The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2023 | MajesTEC-4 & MagnetisMM-7: BsAb maintenance in NDMM with teclistamab & elranatamab
Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on two Phase III trials investigating the use of bispecific antibodies as maintenance therapy for newly diagnosed multiple myeloma (NDMM). MajesTEC-4 (NCT05243797) is currently investigating the use of teclistamab and lenalidomide vs lenalidomide alone, whilst MagnestisMM-7 (NCT05317416) is exploring elranatamab monotherapy versus lenalidomide. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen – research funding, advisory board
Sanofi – advisory board
Takeda – research funding
